Core Insights - The current flu season in 2025 is marked by a significant increase in flu cases, with a 237% year-on-year surge in the sales of Oseltamivir and a 180% increase for the novel antiviral drug Marbofloxacin [1][2] - The predominant strain this year is the H3N2 subtype, which has replaced last year's H1N1, indicating a regular antigenic drift rather than a more dangerous mutation [1] - Flu differs significantly from the common cold, with flu symptoms being more severe and potentially leading to serious complications such as myocarditis, encephalitis, and pneumonia [2] Prevention and Treatment - Vaccination is emphasized as the primary preventive measure, with recommendations for all individuals over 6 months old to receive the flu vaccine, especially vulnerable groups such as the elderly, chronic disease patients, pregnant women, young children, and healthcare workers [2] - This year, 10 manufacturers have approved flu vaccines in China, with prices ranging from 31 to 103 yuan per dose, making them more accessible [2] - In case of infection, it is crucial to use antiviral medications like Oseltamivir or Marbofloxacin within 48 hours of symptom onset for effective treatment [2][3] Supply and Availability - The original manufacturer of Marbofloxacin, Roche, has localized production in Shanghai, increasing the supply to over three times that of last year, ensuring availability in hospitals nationwide [3] - An emergency supply mechanism is in place to address potential outbreaks in specific regions [3]

医院就诊患者多，人群密集，病种复杂，空气流通性弱，如有呼吸道传染病患者就诊，患者排出的病毒 载量也会大于室外环境及其他流通性强的室内环境，面对流感等呼吸道传染病传染性强，传播方式简单 的情况下，感染流感的风险更高，医务人员感染概率也会增加数倍。 "流感疫苗是预防流行性感冒最经济有效的措施。"张婧菲强调，预防流感，要养成良好的健康理念和健 康生活方式，包括减少人群密集性场所活动；打喷嚏要遮住口鼻；勤洗手，多通风；保持良好作息，避 免过度疲劳。科学认识，理性对待，让流感预防更轻松。去医院就诊时，发热患者或者流感疑似患者需 严格按照院内预检分诊进入发热门诊并佩戴医用外科口罩，不乱蹿楼层。就诊完成后尽快离开医疗机 构，不在流感活跃期内逗留。对于医疗机构来说，营造优良的就医环境，减少医务人员和其他患者的感 染，从而可以降低儿童、老年人、慢性病患者患流感后出现重症和死亡的风险。 "多股冷空气接连来袭，许多人出现了鼻塞、咳嗽、流涕症状，通过国家监测，流感也进入了高发季 节，尤其是作为人员密集场所之一，医疗机构是流感传播的高风险区域，需特别注意预防。"青岛市疾 病预防控制中心传染病防制所主管技师张婧菲介绍，流感病毒主要通过打 ...

Core Viewpoint - The article emphasizes the importance of understanding flu prevention and control measures, especially during the high incidence winter-spring season, to protect oneself and family from influenza. Group 1: Influenza Overview - Influenza is an acute respiratory infectious disease caused by the influenza virus, primarily the H3N2 subtype in China [2] - The flu virus has four types: A, B, C, and D, with A and B being the most common in seasonal outbreaks [2] Group 2: Characteristics of Influenza - The flu typically peaks in the winter-spring season, with varying dominant strains each year, including H3N2, H1N1, and B Victoria subtypes [3] - Influenza spreads mainly through droplets from coughs and sneezes, and can survive briefly in the air [4] Group 3: Symptoms and Differences from Common Cold - Typical symptoms of influenza include fever, headache, muscle and joint pain, with temperatures reaching 39-40°C, along with sore throat, dry cough, nasal congestion, and fatigue [5] - Influenza differs from the common cold in terms of causative agents, symptoms, and seasonal patterns, with flu being more severe and often leading to complications like pneumonia in high-risk groups [6] Group 4: High-Risk Groups - High-risk groups for severe influenza include infants, pregnant women, and elderly individuals with chronic conditions such as heart or lung diseases, diabetes, or immune suppression [7] Group 5: Prevention Strategies - Annual vaccination is an effective method to prevent influenza and reduce the risk of severe complications, along with maintaining good personal hygiene and cleanliness in living and working environments [8] Group 6: Response to Symptoms - Individuals showing flu symptoms should rest at home and avoid public places until symptoms subside, and seek medical attention if experiencing severe symptoms like persistent high fever or difficulty breathing [9]

Core Viewpoint - The article emphasizes the significance of understanding influenza, its symptoms, transmission methods, and preventive measures, especially during the winter season when flu cases rise [1][3][8]. Group 1: Differences Between Influenza and Common Cold - Influenza is caused by the influenza virus, while the common cold can be caused by various viruses such as rhinoviruses and coronaviruses [5]. - Symptoms of influenza appear suddenly and are more severe, including high fever (above 38°C) lasting 3 to 5 days, while common cold symptoms develop gradually and usually involve low fever or no fever [6]. - Influenza can lead to serious complications like pneumonia and myocarditis, whereas the common cold has a low risk of complications [6][10]. Group 2: Transmission Methods - Influenza spreads primarily through respiratory droplets when an infected person coughs, sneezes, or talks [3]. - Contact transmission occurs when the virus is transferred from contaminated surfaces to hands and then to the face [3]. - Aerosol transmission can happen in poorly ventilated spaces, increasing the risk of infection [3]. Group 3: Prevention Strategies - Annual vaccination is the most effective way to prevent influenza, recommended for children over 6 months old [8]. - Good personal hygiene practices, such as frequent handwashing and using masks in crowded places, are crucial for prevention [8][9]. - Maintaining a well-ventilated environment and enhancing personal immunity through a balanced diet and regular exercise are also important [8]. Group 4: Management of Influenza Symptoms - Individuals showing symptoms like fever and cough should rest and seek medical attention promptly [10]. - For children, it is advised to wait until they are symptom-free for 48 hours after fever resolution before returning to school to prevent virus transmission [10].

北京儿童医院呼吸中心主任医师 秦强：这次流感的病人又特别多，流行期就会很长，流行期间再接种 也是有意义的。接种疫苗肯定也是有保护作用的。 除了接种疫苗外，还有哪些方式可以预防？对此，专家建议采取"疫苗+卫生习惯"的双防线策略。在接 种疫苗的同时，保持良好的个人卫生习惯。如果出现身体不适，要及时就医，在医生指导下进行相应治 疗。 转载请注明央视财经 编辑：王一帆 （央视财经《正点财经》）冬季是呼吸道传染病的高发期。 目前，全国报告的托幼机构、学校流感聚 集性疫情显著增多，5—14岁病例组的流感检测阳性率明显高于其他年龄组。专家预测，在未来一段时 间内，流感活动还将进一步上升。现在还可以接种流感疫苗吗？ 专家介绍，虽然流感病毒传播已进入高发季，但现在接种疫苗也是有意义的。在未确诊的情况下出现发 热、咳嗽、咽痛等流感样症状，或已经感染过流感病毒痊愈的人群依然可以接种流感疫苗，但不建议正 处在急性发作期的患者接种。 中国疾病预防控制中心研究员 彭质斌：首先，不建议在感染的急性发病期内接种流感疫苗。需要等症 状消失，身体基本恢复后再接种。如果已经出现了流感样症状，在没有确诊、自行痊愈后，这种情况下 可以接种流感疫苗。 ...

Core Viewpoint - The article emphasizes the importance of understanding the flu and its prevention methods, particularly the risks associated with the misuse of antiviral medication Oseltamivir and the necessity of flu vaccination as the most effective preventive measure [2][3][5][10] Group 1: Misuse of Oseltamivir - There are claims that long-term use of Oseltamivir can prevent flu, which experts strongly oppose, stating that the drug should not be used casually [2] - Oseltamivir is effective only when taken within 48 hours of flu symptoms appearing, and its use for post-exposure prevention is limited to high-risk groups [2][3] - Misuse of Oseltamivir can lead to adverse effects such as nausea and potential neuropsychiatric reactions, as well as the risk of developing drug-resistant virus strains [3] Group 2: Understanding Flu vs. Common Cold - The article clarifies that flu is a serious respiratory illness caused by the influenza virus, distinct from common colds caused by other viruses, with significant differences in symptoms and complications [4][5] - Flu symptoms include high fever, muscle aches, and severe fatigue, while common colds typically present milder symptoms [4][5] - The World Health Organization reports that flu can lead to 3 to 5 million severe cases and 290,000 to 650,000 respiratory disease-related deaths annually [5] Group 3: Immunity and Vaccination - Immunity from a previous flu infection lasts only 6 to 8 months, not a lifetime, due to the virus's ability to mutate [6][7] - Vaccination is recommended for everyone aged 6 months and older, with the timing of vaccination being crucial for effectiveness [8][10] - Individuals with mild cold symptoms can receive the flu vaccine, but those with fever or severe symptoms should postpone vaccination [8][9]

Summary of Merck & Co. Investor Call on Acquisition of Sedara Therapeutics Company and Industry - **Company**: Merck & Co. - **Acquisition Target**: Sedara Therapeutics - **Industry**: Pharmaceuticals, specifically focusing on antiviral treatments and infectious diseases Core Points and Arguments 1. **Acquisition Announcement**: Merck announced the acquisition of Sedara Therapeutics, focusing on the innovative antiviral agent CD388 designed to prevent influenza infection in high-risk individuals [4][5][19] 2. **Public Health Need**: Influenza poses a significant public health threat, with the CDC estimating up to 82 million infections, 1.3 million hospitalizations, and 130,000 deaths in the 2024-2025 season [9][10] 3. **CD388 Overview**: CD388 is a first-in-class, long-acting antiviral that has received FDA fast-track and breakthrough therapy designations. It is currently in a phase three trial [5][11] 4. **Market Opportunity**: The potential market for CD388 is estimated to exceed $5 billion, targeting approximately 110 million individuals in the U.S. at high risk for influenza complications [5][17][19] 5. **Clinical Data**: In phase two trials, CD388 demonstrated a remarkable 76% efficacy at the highest dose for preventing influenza-like illness, with low immunogenicity and good tolerability [12][18] 6. **Financial Details**: Merck will acquire Sedara for $221.50 per share, totaling approximately $9.2 billion. The transaction is expected to close in Q1 2026, subject to approvals [19][20] 7. **Impact on Financials**: The acquisition will result in a charge of approximately $9 billion to R&D expenses, impacting EPS by about $0.30 in the first year [20][21] Additional Important Content 1. **Manufacturing Strategy**: Merck plans to transition manufacturing to U.S. facilities over time, moving away from reliance on Wuxi-manufactured products [24][25] 2. **Regulatory Considerations**: CD388 does not require ACIP review for launch, which may streamline its market entry [28][64] 3. **Commercial Model**: The product is expected to fit well within Merck's existing commercial infrastructure, targeting high-risk populations already in healthcare systems [60][79] 4. **Pricing Strategy**: Initial pricing research suggests a potential price point of up to $600, which could facilitate access for patients [61][78] 5. **Future Opportunities**: There is potential for CD388's technology to be applied to other infectious diseases beyond influenza [32][34] This summary encapsulates the key points discussed during the investor call regarding Merck's acquisition of Sedara Therapeutics and the anticipated impact of CD388 on public health and the company's growth trajectory.

Summary of Cidara Therapeutics FY Conference Call Company Overview - Cidara Therapeutics is an 11-year-old biotechnology company focused on developing a universal influenza preventative, CD388, based on its Cloudbreak platform [4][5][6] Core Points and Arguments - **Clinical Development**: CD388 has progressed through preclinical testing and multiple clinical phases, with a successful phase 2b study demonstrating a 76.1% efficacy rate against influenza [7][10] - **FDA Interaction**: The FDA has recommended expanding the phase 3 trial to include high-risk populations, specifically those over 65 years old, in addition to immunocompromised individuals [10][12] - **Phase 3 Study Design**: The ongoing phase 3 study involves 6,000 participants testing the 450 mg dose of CD388 versus placebo, with an interim analysis expected by March 2026 [12][13] - **Efficacy Expectations**: The study is designed to be 90% powered to detect a 60% efficacy rate, with the potential for stronger results if the flu season is severe [12][13] - **Real-World Testing**: The phase 3 study allows for vaccination among participants to assess CD388's effectiveness in both vaccinated and unvaccinated individuals [19][20] Market Opportunity - **Target Population**: Cidara estimates over 100 million patients could be eligible for CD388, including 50 million with moderate to severe comorbidities and another 100 million at increased risk according to CDC guidelines [25][26] - **Pricing and Access**: Ongoing market research is being conducted to understand pricing and access opportunities, with updates expected at the upcoming analyst day [26][27] Manufacturing and Supply Chain - **Manufacturing Plans**: Cidara is preparing to have millions of doses ready at launch, with a focus on establishing a domestic supply chain through a contract with BARDA for onshore manufacturing [29][33] Additional Insights - **Safety and Efficacy**: CD388 is characterized as a long-acting antiviral, distinct from vaccines, and is expected to maintain efficacy throughout the flu season [7][20] - **Regulatory Support**: The FDA has indicated that the phase 2b study could support the registration package, enhancing the potential for a broad label upon approval [23] This summary encapsulates the key points discussed during the Cidara Therapeutics FY Conference Call, highlighting the company's strategic direction, clinical advancements, market potential, and operational plans.

Core Points - The article emphasizes the importance of flu prevention and health, particularly on World Flu Day, highlighting that flu is not just a common cold but a serious illness that can threaten vulnerable populations such as the elderly and children [1] Group 1: Flu Characteristics and Risks - Flu is highly contagious and can lead to severe complications like pneumonia and myocarditis, unlike the common cold which has milder symptoms [5][9] - Vulnerable groups, including children under 5, seniors over 65, individuals with underlying health conditions, and pregnant women, are at higher risk for severe complications from the flu [9] Group 2: Current Flu Situation - The dominant flu strain currently is the H3N2 subtype, with over 90% of positive samples in both southern and northern provinces being this strain [11] - There has been a shift in the dominant flu strain in Shanghai from H1N1 in the first half of the year to H3N2 in the latter half, with typical symptoms including fever, sore throat, and body aches [13]

Group 1 - The core viewpoint of the articles highlights the early onset of the flu season in China, with the H3N2 subtype being the dominant strain, accounting for 95% of the circulating flu viruses [1][2] - The flu activity is currently on the rise, particularly in southern provinces like Guangdong and Hainan, where the positive detection rate for flu viruses is 10%, compared to 6% in northern provinces [1] - Experts confirm that the current H3N2 strain is not a new subtype, and existing vaccines are effective against it, with a higher match rate than in previous years [2] Group 2 - Symptoms of different flu virus subtypes, such as H1N1 and H3N2, are generally similar, including high fever, muscle aches, and respiratory issues, although H1N1 may present more severe symptoms in younger and obese individuals [4][7] - Antiviral treatments like Oseltamivir and Marboxil are crucial for flu management, and it is important to avoid antibiotic misuse as flu is caused by a virus [5][6] - There is a misconception that flu vaccines can cause virus mutations; however, experts clarify that vaccines do not induce mutations and are beneficial in reducing infection risk [10]